References

1. Pieske BM ALDO-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure. European Society of Cardiology 2012 Congress, Munich, Germany at < http://www.eurekalert.org/pub_releases/2012-08/esoc-tas082,612.php>
2. ElGuindy, A. & Yacoub, M. Review article: Heart Failure with Preserved Ejection Fraction. Global Cardiology Science and Practice 2012–10
3. B. a Borlaug, W.J Paulus. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. European heart journal. 2011; 32::670–9
   [Google Scholar]
4. A.S. Desai, et al.. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American heart journal. 2011; 162::966–97.e10
   [Google Scholar]
5. The PARAMOUNT study. at < http://www.eurekalert.org/pub_releases/2012-08/esoc-tps_10,82612.php>
6. S.D. Solomon, et al.. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. The Lancet. 2012 :doi:10.1016/S0140–6736(12)61,227-6
   [Google Scholar]
7. M.P. Lefkowitz. LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension. BMC Pharmacology. 2011; 11::O3
   [Google Scholar]
8. A. Martinez-Rumayor, A.M. Richards, J.C. Burnett, J.L. Januzzi. Biology of the natriuretic peptides. The American journal of cardiology. 2008; 101::3–8
   [Google Scholar]